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Abstract The microaerophilic parasite Giardia lamblia is a
causative agent of dysentery affecting hundreds of millions of
people around the globe every year. The symptoms of the
disease, commonly referred to as giardiasis, are diarrhea, nau-
sea, and malabsorption. Treatment of giardiasis is exclusively
based on chemotherapy with antigiardial drugs, including
metronidazole, albendazole, and nitazoxanide. In this review,
all drugs currently used in the treatment of Giardia infections
are discussed with a special emphasis on treatment failure and
drug resistance.
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Introduction
Giardia lamblia (syn. intestinalis, duodenalis) is a worldwide
occurring protist parasite that causes a form of dysentery com-
monly referred to as giardiasis [1]. Although Giardia infec-
tions frequently present without symptoms and are often self-
limiting, severe gastrointestinal symptoms such as diarrhea,
nausea, bloating, or malabsorption can also ensue. Post-
infection symptoms such as lactose intolerance [2] or irritable
bowel syndrome are not rare [3]. With as much as 33 % of the
population in developing countries having a record of giardi-
asis [4], G. lamblia is considered to be the most common
protist parasite of the human gastrointestinal tract. It prefera-
bly colonizes the small intestine and has a two-staged life
cycle. The acid-resistant, metabolically widely inactive cyst
is ingested by the host and passes through the stomach into
the small intestine. There it excysts and develops into the
trophozoite which is the actively feeding and pathogenic
stage. The trophozoite either moves freely in the lumen or
attaches to the intestinal mucosa. A given proportion of the
trophozoite population undergoes development into cysts
which are excreted in the feces and contaminate water or food.
Upon ingestion of cysts by another host, a new cycle of infec-
tion can commence.
As no prophylaxis against Giardia infections is available,
countermeasures are limited to chemotherapy of established
infections. Fortunately, a comparably large selection of drugs
is available for the treatment of giardiasis. The most common-
ly prescribed drugs are the 5-nitroimidazoles metronidazole
and tinidazole and the benzimidazole albendazole (Fig. 1).
Other drugs used are quinacrine, nitazoxanide, furazolidone,
mebendazole, paromomycin, and bacitracin zinc (Fig. 1).
Auranofin, an approved antirheumatic [5•], and the orphan
drug fumagillin [6•] are highly effective against G. lamblia
and might be introduced as antigiardial drugs in the near
future.
In most of the cases (about 90 %), treatment regimens with
either metronidazole or albendazole alone are effective, but
recalcitrant giardiasis, sometimes due to drug resistance, is
not rare [7]. In such cases, combination therapy regimens of
metronidazole and albendazole or quinacrine are highly effec-
tive [8, 9]. However, it cannot be denied that drug resistance
does occur in G. lamblia, which is a matter of concern due to
the frequent occurrence of this parasite.
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This review will give an overview over the most common
drugs in use against G. lamblia, occurrence and mechanisms
of drug resistance, and other circumstances that may lead to
the failure of treatment.
Antigiardial Drugs
The arsenal of antigiardial drugs is fortunately rather large
although only few drugs are used in daily practice. In fact, in
some countries, e.g., Norway [10], only metronidazole is ap-
proved for the treatment of giardiasis. In addition to the above-
mentioned compounds (Fig. 1), pentamidines [11], chloro-
quine, DL-propanolol, propolis, and ozonized sunflower oil
have been successfully tested against G. lamblia in vitro and
in vivo [12].
Metronidazole, Tinidazole, and Ornidazole
Metronidazole (Fig. 1) is a 5-nitroimidazole drug which was
specifically developed in the late 1950s against another
microaerophilic parasite, Trichomonas vaginalis [13]. Soon
after its discovery, metronidazole was also successfully tested
against numerous other anaerobic and microaerophilic patho-
gens, includingG. lamblia [14], and is nowadays listed among
the Bessential medicines^ by the WHO. Metronidazole is, in
fact, a prodrug which needs to be reduced at its nitro group in
order to become toxic [15]. Due to the very low redox poten-
tial of metronidazole [16], this only quantitatively occurs in
microaerophilic and anaerobic organisms which have a
strongly reductive physiology [17]. In the 13th report on car-
cinogens issued by the NIH [18], metronidazole has been
classified as carcinogenic because it causes tumors in mice
when administered in very high doses. However, no link
between metronidazole treatment and cancer has so far been
observed in humans despite its frequent use. Thus, although
inconvenient side effects are regularly reported, metronidazole
is a rather safe drug in humans and animals. Treatment is
carried out for 5–10 days with one or two doses per day [12].
Metronidazole damages DNA in microaerophiles and an-
aerobes [19], obviously by introducing double strand breaks
[20•]. In addition, metronidazole binds to free thiols, such as
cysteine, which has a similar role in many microaerophilic
parasites as glutathione has in mammalian cells [21–24].
Metronidazole also forms covalent adducts with cysteines in
proteins. Specifically, metronidazole targets the redox enzyme
thioredoxin reductase in Entamoeba histolytica, Trichomonas
vaginalis, and G. lamblia and inhibits the enzyme’s function
as a disulfide reductase [21, 22, 24]. All these events result in
severe oxidative stress. This is further corroborated by the
observation that cysteine, added to the growth medium, pro-
tects Giardia from metronidazole [25]. In G. lamblia, metro-
nidazole also leads to the degradation of elongation factor 1-γ
(EF1-γ), an enzyme involved in protein translation [23]. The
mode of action of other 5-nitroimidazoles, e.g., tinidazole and
ornidazole, is very likely to be identical [21]. However,
tinidazole and ornidazole are more efficacious than metroni-
dazole because they have considerably longer serum half-lives
than metronidazole [12] and can be administered as single
doses of 1 or 2 g. As a result, they have a better patient com-
pliance than metronidazole.
Albendazole and Mebendazole
The benzimidazole drug albendazole (Fig. 1) was approved in
1983 for the treatment of helminth infections and was soon
found to be efficacious against G. lamblia as well [26–28].
When given in single 400 mg doses for 5 days, it is equally
Fig. 1 Antigiardial drugs: metronidazole (1), albendazole (2), furazolidone (3), nitazoxanide (4), paromomycin (5), and bacitracin (6). All images are
taken from wikipedia.org
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effective as metronidazole but has fewer side effects because it
is poorly absorbed in the human gut [29]. Consequently,
albendazole therapy against giardiasis is an alternative to met-
ronidazole therapy. Another benzimidazole, mebendazole,
was also found to be effective against G. lamblia [27].
Treatment courses with mebendazole, however, have been
reported to be variably effective [30–33]. For both,
albendazole and mebendazole, teratogenic effects in rats were
reported [12].
One confirmed target of benzimidazoles is β-tubulin [27,
3], a major component of the cytoskeleton in G. lamblia [35].
Albendazole and mebendazole bind very efficiently to β-
tubulin in susceptible organisms [36], including G. lamblia,
thereby leading to the inhibition of cytoskeleton polymeriza-
tion and, consequently, to severe structural defects [37].
Nitazoxanide
The nitrothiazolide compound nitazoxanide (Fig. 1) was first
described as antihelmintic [38] but later also found to be active
against a range of other parasites including Giardia lamblia
[39]. In 2004, it was approved in the USA for the pediatric
treatment of giardiasis. As is the case with 5-nitroimidazoles,
nitazoxanide has to be reduced at the nitro group for activity in
Giardia [40]. Nitazoxanide is usually prescribed for 3 days
and well tolerated because it is poorly absorbed in the intestine
[12]. No evidence for any mutagenic or teratogenic activity of
nitazoxanide has been found so far.
The mode of action of nitazoxanide is very likely to be
multifactorial. Nitazoxanide strongly inhibits the pyruvate
decarboxylating enzyme pyruvate:ferredoxin oxidoreductase
(PFOR), an enzyme of central physiological importance in
G. lamblia [41]. However, nitazoxanide also inhibits other
enzymes, such as nitroreductase 1 [42], a presumptive qui-
none reductase [43], and compromises the integrity of the cell
by causing lesions in the ventral cell membrane and inducing
vacuolization [40].
Quinacrine
The acridine drug quinacrine (Fig. 1) was originally intro-
duced as an antimalarial but also used for the treatment of
giardiasis after the Second World War [34]. The drug is very
effective but must be given over 5–10 days and frequently
causes side effects such as nausea or discoloration of the skin.
Its mode of action has been scarcely studied, but it was found
to inhibit nucleic acid synthesis [44] In G. lamblia, however,
no evidence was found that quinacrine accumulates in the
nucleus [45]. As is the case with metronidazole, quinacrine
toxicity is counteracted by cysteine [25], suggesting that the
drug’s mode of action includes induction of oxidative stress.
Currently, quinacrine is only used as a second-line therapeutic
in combination with metronidazole or albendazole.
Paromomycin
Effectiveness of the aminoglycoside paromomycin (Fig. 1)
against G. lamblia was first reported in 1989 [46]. The effica-
cy of the drug, however, greatly varies among laboratories
[46, 47], and in one instance, no effect of paromomycin on
G. lamblia was observed at all [48]. Paromomycin has been
rarely used in the treatment of giardiasis but its particular
advantage is that it is practically not absorbed by the intestine,
rendering it safe for use during pregnancy [34]. It is effective
as a second-line drug in combination with metronidazole [49].
Furazolidone
Like the 5-nitroimidazoles and nitazoxanide, the nitrofuran
furazolidone (Fig. 1) is a prodrug whose nitro group must be
reduced in order to be rendered active [50, 51]. It has a higher
redox potential than 5-nitroimidazoles and is therefore more
efficiently reduced in microaerophilic parasites [22, 52]. The
reduced intermediates of furazolidone likely damage cell con-
stituents such as DNA and proteins [34]. A related nitrofuran,
nifurtimox, was reported to bind to thiol groups [53] and to
lower free thiol concentrations in Trypanosoma cruzi [54].
Furazolidone is clinically highly effective when adminis-
tered for 7–10 days, but shorter courses yield lower cure rates.
One great advantage of furazolidone is its availability as a
liquid suspension which has a higher compliance with
children.
Bacitracin Zinc
The polypeptide antibiotic bacitracin (Fig. 1) was found to be
effective against G. lamblia in 1994 [55] and was even
several-fold more so in combination with zinc. To date, only
one clinical trial for treatment of giardiasis with bacitracin zinc
was performed [56]. Although bacitracin zinc treatment was
effective, it had to be continued for 10 days which negatively
affects patient compliance [34].
Treatment Failure and Drug Resistance in G. lamblia
Most clinical studies on chemotherapy of giardiasis demon-
strate that, regardless of the drug used, cure rates are normally
below 100 %. Apart from drug resistance, other factors can
also be responsible for treatment failure, such as reinfection,
insufficient amounts of drug administered, immunosuppres-
sion, or sequestration in the gallbladder or the pancreas [9].
If two or more courses of treatment with a given drug are
unsuccessful, it is recommended to either use another drug
alone or in combination with the first drug [9, 34]. Most of
the refractory cases can be ultimately cured with the arsenal of
antigiardial drugs available. This is very well illustrated in a
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careful study on a chosen treatment regime during an outbreak
of giardiasis in Norway. A treatment ladder was applied in
order to minimize the number of patients remaining uncured
after treatment [8]. Thirty-eight individuals out of more than
1200 treated in total were not cured from giardiasis after one to
three courses of metronidazole therapy. As a next step, the
refractory cases were treated with a combination of metroni-
dazole and albendazole, resulting in the cure of 30 patients.
The eight patients, neither responding to metronidazole nor to
albendazole, were treated with paromomycin, resulting in the
cure of four. The remaining four patients were finally cured
after 3 weeks of treatment with a combination of quinacrine
and high doses of metronidazole. Importantly, the combina-
tion of metronidazole and quinacrine was also found by others
to be effective in eliminating refractory G. lamblia infections
[9, 57].
It is important to note thatG. lamblia isolated from patients
with refractory giardiasis do not always display drug resis-
tance in vitro [57], suggesting some physiological influence
of the human host on the success of a given chemotherapy. It
is, therefore, important to rule out that people with recurrent
symptoms have not been re-infected and that they are not
suffering from lactose intolerance or irritable bowel syndrome
which frequently evolves after giardiasis [2, 3].
No reports or studies on resistance to the more rarely used
antigiardial drugs, bacitracin zinc and paromomycin, have
been published, but resistance in G. lamblia to 5-
nitroimidazoles, albendazole, nitazoxanide, quinacrine, and
furazolidone has been studied to varying extent.
Resistance to Metronidazole and Other 5-nitroimidazoles
Metronidazole resistance has been intensely studied in
microaerophilic and anaerobic pathogens, including
G. lamblia. Indeed, resistantGiardia strains have been repeat-
edly isolated from patients with refractory giardiasis [58, 59].
In addition, resistance to metronidazole and other 5-
nitroimidazoles is relatively easy to induce in the laboratory
by exposing Giardia to incremental doses of drug or to UV
light [7, 42, 60–62]. Eventually, tolerance to metronidazole
can be increased to more than the 100-fold the IC50 of the
drug in sensitive isolates [61].
The mechanisms of metronidazole resistance have been
widely discussed throughout the last 40 years, but the obser-
vations made are often conflicting and difficult to put into
perspective. Two factors that have been understood as being
central for the reduction, i.e., activation of 5-nitroimidazoles,
are pyruvate ferredoxin oxidoreductase (PFOR) and its cofac-
tor ferredoxin which are almost always present in
microaerophilic and anaerobic organisms [63]. As shown in
several organisms, including Giardia, ferredoxin is reduced
by PFOR and can transfer an electron to the nitro group of
metronidazole [16, 64–66]. In accordance, slightly reduced
PFOR activities were measured in Giardia stocks with re-
duced sensitivity to metronidazole [67] and some
metronidazole-resistant strains generated in the laboratory,
e.g., BRIS/83/HEPU106-2ID10, have only remnant PFOR ac-
tivity [68, 69]. Further, a knock-down of PFOR expression
using hammerhead ribozymes rendered Giardia resistant to
metronidazole [70]. In contrast, however, metronidazole-
resistant cell lines with an intact PFOR/ferredoxin pathway,
e.g., BRIS/87/HEPU/713-M3, were described [69].
Moreover, Giardia cell lines resistant to C17, a second-
generation 5-nitroimidazole [71], are highly cross-resistant
to metronidazole but have fully functional PFOR and ferre-
doxin [69]. Thus, inactivation of the PFOR/ferredoxin path-
way is not a prerequisite for 5-nitromidazole resistance. In a
series of research papers, it was shown that nitroreductase 1
and 2 could have an important role in the metabolism of met-
ronidazole in Giardia. Interestingly, nitroreductase 1 can acti-
vate metronidazole to reactive metabolites [72], whereas
nitroreductase 2 has, conversely, a protective effect, possibly
through fully reducing the drug’s nitro group with six elec-
trons to a non-toxic amino group [73•]. In accordance with
this notion, expression of nitroreductase 1 was found to be
downregulated in metronidazole-resistant laboratory cell lines
[72, 73•], whereas nitroreductase 2 was found to be upregu-
lated [73•]. Furthermore, overexpression of nitroreductase 2
renders Giardia more tolerant to metronidazole [73•].
Expression of thioredoxin reductase (TrxR) [21, 22, 69], how-
ever, i.e., another factor that can reduce 5-nitroimidazoles, was
not found to be affected in metronidazole-resistant Giardia
cell lines [69].
In any case, it is certain that reduced metronidazole sensi-
tivity in clinical Giardia isolates on the one hand and fully
developed metronidazole resistance induced in the laboratory
on the other are caused by different underlying mechanisms.
Metronidazole-resistant cell lines generated in the lab do hard-
ly establish infections in mice, indicating that the physiologi-
cal adaptations necessary to tolerate high doses of metronida-
zole have high fitness costs [74]. Also in another
microaerophilic parasite, Trichomonas vaginalis, metronida-
zole resistance in clinical isolates is fundamentally different
from metronidazole resistance generated in the laboratory
[75–78]. In metronidazole-resistant clinical T. vaginalis iso-
lates, no downregulation or inactivation of factors that reduce
5-nitroimidazoles can be observed [23, 76, 79]. Instead, the
oxygen scavenging capability is impaired [76], leading to
higher intracellular oxygen concentrations. Since oxygen
quickly re-oxidizes nitroradical anions to the non-toxic
prodrug, these strains are highly resistant to metronidazole if
oxygen is present [80] but normally susceptible to the drug
when oxygen levels are low [75]. Presumably, downregula-
tion of flavin reductase 1 [81], which reduces oxygen to hy-
drogen peroxide by using FMN and NADPH as cofactors, is a
key event in the development of clinical metronidazole
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resistance in T. vaginalis. NADPH-dependent reduction of
oxygen via FMN can also be observed in G. lamblia [68]
but is catalyzed by another, yet undescribed, enzyme because
T. vaginalis flavin reductase 1 has no homologue in the
G. lamblia genome. Confusingly, this enzyme activity is
downregulated in metronidazole-resistant G. lamblia lab-
oratory cell lines [69] but strongly upregulated in clin-
ical isolates with reduced metronidazole sensitivity [68].
Thus, for all the research efforts of the last decades, our
understanding of metronidazole resistance in G. lamblia
is still incomplete at best.
Resistance to Nitazoxanide
Although nitazoxanide resistance has not been observed yet in
the clinic, it can be induced in the laboratory [42]. In one
study, a nitazoxanide-resistant cell line was strongly cross-
resistant to metronidazole, whereas a cell line with induced
metronidazole resistance was fully susceptible to nitazoxanide
[42], indicating that cross resistance between both drugs is not
necessarily reciprocal. In another study, however, laboratory
cell lines, adapted to high concentrations of metronidazole,
also displayed a similar level of resistance towards
nitazoxanide [74]. An expression study on the nitazoxanide-
resistant cell line showed several protein chaperones such as
Hsp70, Hsp90, and Cpn60, and several surface antigens to be
upregulated in expression [82]. Levels of PFOR were
practically unaltered in nitazoxanide-resistant cell lines [42],
but nitroreductase 1 was found downregulated [72].
Overexpression of nitroreductase 2, however, has no protec-
tive effect in Giardia against nitazoxanide [73•]. In summary,
resistance mechanisms against metronidazole and
nitazoxanide do partially overlap but are not identical.
Resistance to Albendazole
Resistance to albendazole has been repeatedly observed in
clinical isolates [58, 59] and in the laboratory [62, 83–85].
Indeed, Giardia can be adapted to concentrations of
albendazole that are about 1000-fold higher than the IC50 of
the drug in susceptible stocks [85]. In helminths, benzimid-
azole resistance is usually conferred by mutations in the β-
tubulin gene, preferably at amino acid positions 167 and 200
[86]. InGiardia, however, conflicting observations have been
made in this regard. In one study, an altered amino acid se-
quence of β-tubulin upon extended exposure to increasing
concentrations of albendazole was identified [84], whereas
others found no alterations in the sequence [45, 62]. Instead,
chromosomal rearrangements, cytoskeletal aberrations [45],
and the altered expression of several genes, including a
VSP-like protein [62], constituents of the ventral disk (α2-
giardin) or various enzymes such as NADH oxidase and
triosephosphate isomerase [85], were found in albendazole-
resistant cell lines. Interestingly, also PFOR was reported
to be upregulated in albendazole-resistant cell lines [62].
The implications of these findings are still unclear as yet,
but they suggest that benzimidazoles probably target a
more diverse group of molecules in G. lamblia than in
helminths.
Resistance to Furazolidone
Based on electron paramagnetic resonance (EPR) spectra, the
enzyme NADH oxidase was suggested to be an activator of
furazolidone in G. lamblia by donating an electron to the
drug’s nitro group [52]. Reduction of the nitro group gives
rise to a nitroradical anion which is believed to be the actual
toxic agent. However, although resistance to furazolidone can
be induced in vitro [61], no correlation between NADH
oxidase activity and furazolidone resistance has been
reported as yet. Also, PFOR activity was not altered
in furazolidone-resistant Giardia [15]. In fact, due to
the relatively high reduction potential of nitrofurans, at
least in comparison with nitroimidazoles, quantitative
reduction of furazolidone might already take place as
soon as reduced flavin (either free or bound to proteins
as cofactors) is present in the cell [87].
In clinical isolates which demonstrate reduced sensitivity to
furazolidone, thiol-dependent peroxidase and reductase activ-
ities were reported to be increased [67]. These activities can be
attributed most likely to peroxiredoxin and thioredoxin reduc-
tase, respectively. It is reasonable to assume that higher levels
of these enzymes render Giardia more tolerant to reactive
oxygen species which are generated by redox cycling of fura-
zolidone nitroradical anions. Still, it is questionable whether
these enhanced enzyme activities can account for the far more
pronounced resistance induced in vitro [61]. Importantly,
strains with previously induced furazolidone resistance can
be adapted to high concentrations of quinacrine much easier
than wild type, suggesting the existence of a common drug
export mechanism [45]. However, Giardia laboratory cell
lines with metronidazole resistance also tolerate more furazol-
idone [74], albeit to a far lesser degree as compared to
metronidazole.
Resistance to Quinacrine
Only few data on quinacrine resistance inG. lamblia are avail-
able. However, in a careful study resistance to quinacrine was
gradually induced in vitro in several strains [45]. Eventually,
resistant cell lines were able to grow at concentrations about
50-fold higher than the normal IC50 [88]. Fluorescence anal-
ysis suggested that the drug is excluded from resistant
G. lamblia [45].
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Conclusions
It is unlikely that the management of giardiasis will be com-
promised in the future by a lack of treatment options.
Although treatment failures and drug resistance in Giardia
can be problematic, a comparably large number of effective
drugs are available, and combination therapy is almost always
successful. Moreover, promising novel treatment options have
been presented recently, such as formononetin [89, 90],
auranofin [5•] and fumagillin [6•], and natural products with
antigiardial activity have remained an as yet untapped source
[91].
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